Market Overview

Benzinga's Volume Movers

Related VRTX
Vertex Pharmaceuticals' Recuperation Will Continue, Vetr Crowd Says
Vetr Crowd Says Buy Vertex Pharmaceuticals
How Does Brexit Affect Biotech Stocks? Wall Street Weighs In (Investor's Business Daily)
TG Therapeutics Reports TGR-1202 in Combo with Ibrutinib, Recaps Long-Term Safety, Efficacy Data of TGR-1202 in CLL, NHLs
Benzinga's Top Initiations

Vertex Pharmaceuticals (NASDAQ: VRTX) shares moved up 41.68% to $94.37. The volume of Vertex Pharmaceuticals shares traded was 2978% higher than normal. Vertex Pharma reported that its two phase 3 study of Lumacaftor in combination with ivacaftor met the primary endpoint.

TG Therapeutics (NASDAQ: TGTX) shares rose 6.91% to $10.36. The volume of TG Therapeutics shares traded was 442% higher than normal. TG Therapeutics completed a licensing agreement with Ligand Pharma (NASDAQ: LGND) to develop inhibitors of IRAK4. (NASDAQ: WIX) surged 6.87% to $18.99. The volume of shares traded 333% higher than normal. announced that it had surpassed 50 million registered users worldwide.

Voxeljet AG (NASDAQ: VJET) shares climbed 3.71% to $18.15. The volume of Voxeljet shares traded was 200% higher than normal. Voxeljet's trailing-twelve-month revenue is $16.39 million.

Posted-In: volume moversNews Intraday Update Markets Movers


Related Articles (LGND + TGTX)

View Comments and Join the Discussion!